At present, 安尼可^® is the only PD-1 monoclonal antibody that applies the immunoglobulin G1 (‘‘IgG1’’) subtype modified by the fragment crystallizable (Fc) segment in the world, which has a lower antigen binding off-rate and a unique binding epitope as demonstrated by analysis on crystal structure. These features allow 安尼可^® to effectively and continuously block PD-1/PD-L1 binding, thus differentiating it from PD-1 products on the market, and may enable安尼可^® to more effectively enhance immunotherapeutic efficacy and reduce immune-related adverse reactions. The main indications for安尼可^® include lung cancer, liver cancer, gastric cancer, nasopharyngeal cancer, esophageal cancer, classical Hodgkin’s lymphoma, mesothelioma, thymic cancer, urothelial cancer, bile duct cancer and neuroendocrine cancer. Currently,安尼可^® has been approved by the National Medical Products Administration of China (NMPA) for ：first-line treatment of recurrent or metastatic nasopharyngeal cancer (NPC) in combination with chemotherapy; first-line treatment of locally advanced or metastatic squamous NSCLC; treatment of relapsed or refractory classical Hodgkin's lymphoma (r/r cHL) after at least second-line systemic therapy; and third-line treatment of metastatic nasopharyngeal cancer chemotherapy. 安尼可^® (penpulimab-kcqx) has also been granted marketing approval by the FDA in two BLA indications for comprehensive treatment of advanced nasopharyngeal carcinoma (NPC) ：first-line treatment of adult recurrent or metastatic non-keratinizing NPC in combination with cisplatin or carboplatin and gemcitabine;monotherapy for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and with at least one other prior line of therapy.